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Abstract
Hepatitis delta virus (HDV) infects hepatocytes, the major cell type of the liver. Infection of the liver may be either transient
or chronic. The prognosis for patients with chronic HDV infection is poor, with a high risk of cirrhosis and hepatocellular
carcinoma. The best antiviral therapy is weekly administration for at least one year of high doses of interferon alpha. This
efficacy of interferon therapy has been puzzling in that HDV replication in transfected cell lines is reported as insensitive to
administration of interferon alpha or gamma. Similarly, this study shows that even when an interferon response was
induced by transfection of poly(IC) into a cell line, HDV RNA accumulation was only modestly inhibited. However, when the
HDV replication was initiated by infection of primary human hepatocytes, simultaneous addition of interferons alpha or
gamma at 600 units/ml, a concentration comparable to that achieved in treated patients, the subsequent HDV RNA
accumulation was inhibited by at least 80%. These interferon treatments were shown to produce significant time-
dependent increases of host response proteins such as for Stat-1, phosphoStat-1, Mx1/2/3 and PKR, and yet interferon
pretreatment of hepatocytes did not confer an increased inhibition of HDV replication over interferon treatment at the time
of (or after) infection. These and other data support the interpretation that interferon action against HDV replication can
occur and is largely mediated at the level of entry into primary human hepatocytes. Thus in vivo, the success of long-term
interferon therapy for chronic HDV, may likewise involve blocking HDV spread by interfering with the initiation of
productive infection of naı ¨ve hepatocytes.
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Introduction
Hepatitis delta virus (HDV) was initially discovered because it
can induce an acute exacerbation of chronic hepatitis B virus
(HBV) infections [1]. HDV is now known to be a subviral agent
that requires the envelope proteins of HBV for infection of
hepatocytes and for assembly of new virus particles [2]. About
75% of patients chronically infected with both HDV and HBV will
develop liver damage at a significantly greater rate than patients
infected with HBV alone [3].
As a preventive measure, strategies that block HBV infection
also block HDV. Thus, the recombinant HBV vaccine comprised
of the HBV envelope proteins is the best strategy for preventing
both HBV and HDV infections. Worldwide adoption of this
vaccination strategy has decreased the incidence of HBV
infections, and in turn, HDV because it is dependent upon
HBV as a helper virus [4,5].
On the other hand, once HDV infections have occurred and
become chronic in an HBV carrier, nucleoside analog inhibitors of
HBV replication do not lead to significant decreases in HDV [4].
Currently, the best therapy for chronic HDV infection involves
treatments of up to 2 years with weekly injections of high doses (9
million units) of pegylated interferon alpha [4,6,7] which is also
active against HBV. Even then, the success rate for such
treatments only ranges up to 43%.
Despite this level of success of interferon alpha therapy in vivo,
treatment with interferons has no effect in cell lines that are
supporting HDV replication [8,9,10]. In fact, a recent report
indicated that HDV replication can interfere with the ability of the
cell to respond to interferon [11]. Here we have confirmed and
extended the understanding of how HDV RNA replication might
interfere with responsiveness. Our findings include evidence that
HDV RNA replication in cell lines can be modestly inhibited if
interferon expression is induced. We have also made use of
primary human hepatocytes that are susceptible to infection by
HDV. With such a system, we find that treatments with interferons
alpha or gamma, have a significant effect especially when applied
around the time of initiation of HDV replication. In summary, we
here resolve what has been an apparent disagreement between in
vivo and in vitro studies, and hopefully clear the way for rational
improvements in therapies for chronic HDV infections.
Results
As described above, previous studies with transfected cell lines
indicate that HDV RNA accumulation is resistant to the
application of interferon treatments. In addition, HDV RNA
accumulation might actually interfere with the cellular response to
interferon. To address this latter possibility we made use of two cell
lines derived from 293 cells, a human embryonic kidney derived
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small antigen, with expression under TET control [12]. By 24 h
after TET induction, millions of copies of dAg accumulate per cell,
without toxicity or significant effect on expression of cellular genes
[12,13]. This cell line was transfected with HDV RNA to produce
the 293-HDV cell line. After 24 h of TET induction, these cells
accumulate not only dAg but also ,40,000 copies of HDV
genomic RNA, and a smaller amount of antigenomic HDV RNA.
As described by Guo et al. [14] we induced an interferon response
in these two cell lines by transfection with poly(IC) at 6 h before
TET induction. The response was measured after 24 h of TET
induction, by assaying for interferon-beta1 mRNA.
As shown in Fig. 1A, transfection of 293-dAg cells with
increasing amounts of poly(IC) produced a robust induction of
interferon-beta1 mRNA in the absence of TET induction of dAg
synthesis. When dAg was induced by TET interferon-beta1
mRNA accumulation was reduced 2-fold. As shown in Fig. 1B for
293-HDV cells, HDV RNA accumulation reduced interferon
beta1 induction by an additional 2-fold.
Our findings are thus is in agreement with the report of Pugnale
et al. [11] that HDV can suppress innate immunity, albeit
incompletely. In addition, as shown in Fig. 1C, there was a modest
effect, associated with the poly(IC) transfection, on the ability of
the induced cells to accumulate HDV RNA.
Some caution is nevertheless needed in interpreting this
inhibition of interferon induction since we have previously shown
for 293-HDV cells, using whole genome mRNA array analysis,
that TET induction alone, in the absence of poly(IC), is sufficient
to produce in 24 h greater than 2-fold changes, increases or
decreases, in more than 1,000 host mRNA [13]. And, these were
not in genes associated with the innate immune response.
We next turned our attention to whether the application of
interferons alpha and gamma could affect the ability of primary
human hepatocytes to support HDV infection [15]. In this system,
HDV is not secreted since HBV is not present, but HDV genome
replication, which is not HBV-dependent, still takes place. Thus,
we can study the effect of these interferons in the absence any
competition with HBV, and in the absence of virus assembly and
spread. Interferons alpha and gamma were applied at 600 units/
ml. We estimated this would be the theoretical maximum
therapeutic concentration of interferon alpha in a patient injected
with 3 million units in a blood volume of 5 liters.
Our experimental procedure was to expose the hepatocytes to
virus for only 3 h. The potential inhibitors were applied at
different times relative to this. HDV RNA levels were measured 6
days post-infection, using realtime PCR. The time-lines of such
treatments with virus and inhibitors are represented in Fig. 2, and
the results are summarized in Table 1. It can be seen that
significant inhibition was obtained when either interferon was
applied during the period of virus exposure but less so after 16 h,
when virus replication was initiated.
As a control for these studies we used a synthetic peptide that
blocks HDV infection by inhibiting virus entry into hepatocytes
but has no effect on viral genome replication in infected
hepatocytes. Previous studies by Urban and others have shown
that the N-terminal region of the large envelope protein of HBV is
necessary for infectivity of HBV, and also of HDV [16,17,18,19].
Furthermore, chemically synthesized forms of this region give
strong inhibition of infection both with cultured cells and even in
vivo, in mice transplanted with human hepatocytes [20]. The
chemically synthesized peptide, referred to as preS1 peptide, is 47
amino acids long with an N-terminal myristoylation and was used
at 50 nM. As shown in Table 1 this peptide strongly inhibited
HDV infection when present during the 3 h of exposure to virus.
Figure 1. Transfection of poly(IC) into 293-dAg and 293-HDV
cells, with and without TET induction. Panel A: 293-dAg cells in a
24-well format were transfected with the indicated amounts of poly(IC)
and after 6 h induced with or without TET. At 24 h total RNA was
extracted and assayed by realtime PCR for interferon-beta1. Panels B
and C: As in A, but using 293-HDV cells. In B and C the assays are for
interferon-beta1 and HDV RNA, respectively. The experiment was
performed in triplicate. Values are expressed in arbitrary units along
with the standard error of the mean which includes the errors in both
the control and the treated cultures.
doi:10.1371/journal.pone.0022415.g001
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period (64 h), it had little effect. Similar to the preS1 peptide, the
primary effect of applying interferons alpha and gamma occurred
at the time of infection (Table 1). And, consistent with the studies
in cell lines, interferon application had less effect once the
hepatocytes were infected (Table 1).
Interferon treatments can induce an innate response but this
outcome can be host cell specific [21,22]. Therefore, it was
obligatory to test whether that our experimental conditions
induced such a response in the cultured primary human
hepatocytes. Using immunoblot assays we found, as shown in
Fig. 3, that both interferons at 600 units/ml induced time-
dependent changes of known host innate response proteins in the
primary hepatocytes. Increases were seen for Stat 1, pStat 1, Mx-
1/2/3 and PKR. Interferon alpha had more effect than interferon
gamma. As expected no changes were detected for beta-actin.
Because this induction of proteins associated with host
immunity was greatest after 24 h of treatment (Fig. 3) we next
asked if pretreatment with interferon enhanced the inhibition of
HDV replication. At the same time we performed a dose response
curve for interferon alpha and the preS1 peptide. The results are
summarized in Fig. 4. The extended pretreatment did not increase
the action of interferon alpha or the preS1 peptide. This result
further supports the interpretation that inhibition is largely
achieved during and/or soon after virus entry. For the preS1
peptide we expect the inhibition to be during rather than after
virus entry.
Note that we calculated that 600 units/ml of recombinant
interferon alpha is equivalent to 0.12 nM. Thus while preS1
peptide is inhibitory, on a molar basis it is about 300-times less
active than the recombinant interferon alpha.
We also compared the sensitivity of VSV infection of primary
hepatocytes to interferon alpha. For this we used a modified VSV
that expresses GFP. VSV not only replicates faster than HDV but
also will release new virus that can spread to uninfected cells.
Therefore, we reduced the multiplicity of infection to about 0.01,
and limited the VSV exposure of hepatocytes to 16 h, without and
with increasing doses of interferon. At 16 h post-infection GFP
positive cells were counted. As shown in Fig. 4, the action of
interferon alpha was potent with 1 pM (6 units/ml) giving .90%
inhibition, and $3 pM (20 units/ml) giving .99.5% inhibition.
Thus inhibition of VSV in primary hepatocytes is achieved at
molar concentrations of interferon about 1,000 times lower than
required for HDV.
Discussion
Studies by others have shown that efficient inhibition of VSV
replication by interferon is multi-faceted and related to induction of
a host innate response [23] just as we confirmed here for VSV and
primaryhuman hepatocytes (Figs. 3 and 4).The observed inhibition
of HDV replication was real but less efficient, requiring much
higher molar concentrations of interferon (Fig. 4). This efficiency
was not increased by the addition of a prior interferon treatment
(Table 1 and Fig. 4). And, since there was less inhibition when the
interferon was added for a much longer period but after the
initiation of infection (Table 1), we suggest that for HDV infections,
interferons act primarily during the process of virus entry. Our
interpretation could explain why previous in vitro studies that used
HDV transfection rather than infection, demonstrated little
antiviral activity of interferon treatment. Additional support for
our explanation is as follows. In previous studies we and others have
found that HDV entry into susceptible cells is a slow process
[18,24]. Of the virus that attaches to cells within a 3-h period of
exposure, the majority requires as much as 16 h more before virus
entry is achieved. Such data have been obtained using as inhibitor
the preS1 peptide synthesized and characterized by Urban and
coworkers [18,19]. It acts after virus attachment, in the slow but as
yet unexplained process of virus entry [18]. In the present studies
interferons were like preS1 peptide in terms of the dependence of
the achieved effects on the time of inhibitor exposure relative to the
period of virus exposure (Table 1). Thus we assert that interferons
are largely acting in the same way. There are other agents that act
predominantly at HDV entry into primary human hepatocytes.
These include suramin, BBG, PPADS, and to a lesser extent
heparin [24]. On a molar basis, these agents are much less active
than the preS1 peptide, which in turn is much less active than the
interferons (Fig. 4). However, as a unifying hypothesis, we suggest
they all act largely by perturbations of a slow multi-step process by
which virus entry is achieved.
At the same time we also understood that under certain
situations, interferons can affect HDV replication at steps other
Figure 2. Representation of time-lines for exposure of primary
hepatocytes to HDV and potential inhibitors. For the five time-
lines shown the open box indicates the period of HDV exposure and the
shaded box the exposure to inhibitor. The effects on HDV replication of
such treatments with three different inhibitors are summarized in
Table 1.
doi:10.1371/journal.pone.0022415.g002
Table 1. HDV replication is inhibited by application of
interferons alpha or gamma.
% HDV replication in presence of inhibitor
Time when inhibitor
present (hours) PreS1 peptide IFN-alpha IFN-gamma
21t o+39 661 9 652 0 612
21t o+16 4628 621 5 610
+3t o+16 9661 7 683 8 621
+16 to +80 65636 37617 40623
Times of addition of inhibitors are measured relative to 3-h of virus exposure.
The preS1 peptide was present at 50 nM while the interferons were at 600 U/
ml. All assays were performed in at least triplicate, and the data expressed
relative to control hepatocytes that were not treated with inhibitors. The
indicated standard error of the mean includes the errors in both the control and
the treated cultures.
doi:10.1371/journal.pone.0022415.t001
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effect of interferon treatments on inducible HDV RNA synthesis
and accumulation. In this earlier study using 293-HDV cells there
was no of evidence of a host response to the interferon [8].
However, here we document that following transfection with
poly(IC), there is an induction of interferon beta1 and a modest 2-
Figure 3. Time-dependent induction by interferons alpha and gamma of innate immune response proteins in primary hepatocytes.
Hepatocytes were exposed to either interferons alpha or gamma at 600 units/ml. At time points out to 24 h, as indicated, total cell protein was
extracted and analyzed by immunoblot to detect the indicated host proteins. Note that after 2 hours of treatment with interferon gamma, the
pSTAT1 increases but not the total STAT1; this is because only a small fraction of the total STAT1 undergoes phosphorylation.
doi:10.1371/journal.pone.0022415.g003
Figure 4. Dose response of HDV and VSV infections to interferon-alpha and preS1 peptide. For HDV infections the inhibitors were
present from 24 h prior to infection and during the 16 h of exposure to virus. Replication was assayed at 6 days post-infection by realtime PCR, as in
Fig. 1C. The assays were performed in triplicate, and average values are expressed as a percentage relative to the untreated controls, with the
indicated standard error of the mean. For the VSV infections, the interferon was only present during the 16 h of virus exposure. VSV replication was
assayed at 16 h by counting GFP positive cells. The values are expressed relative to untreated controls and the errors indicate the standard deviation
as the square root of the mean. Interferon-alpha concentrations are expressed here as molarities, with 600 units/ml=0.12 nM. The preS1 peptide, like
interferon-alpha, can inhibit HDV infection, but the needed molarity is 300-times more. Interferon-alpha can inhibit VSV infection but the
concentration is 1,000-time less than that needed to inhibit HDV.
doi:10.1371/journal.pone.0022415.g004
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the converse situation and observed that HDV RNA accumulation
interfered with the poly(IC) response (Fig. 1B). It did have a 4-fold
effect, and in this we agree with the studies of Pugnale et al. [11].
However, we also found that expression of dAg alone, in the
absence of HDV RNA accumulation, was sufficient for a 2-fold
effect (Fig. 1A).
Pugnale et al. did find that after HDV replication was induced
by transfection of liver cell lines, there was inhibition of the ability
of interferon to induce host response genes [11]. As part of a
strategy for additional testing of this in vitro phenomenon, we used
HDV infection to achieve infection of .1% of all cultured
hepatocytes. Then at 5 days after HDV exposure, we determined
whether cells could still be infected within 16 h by VSV and
whether 20 units/ml of interferon present during this 16 h would
inhibit the VSV. If HDV replication were to specifically suppress
the interferon response, then the VSV would now replicate in the
HDV infected cells. However, by immunostaining for dAg and
GFP, we found that VSV was only able to infect cells not infected
by HDV, and that the VSV infection was inhibited by the
interferon application (data not shown). Thus, prior HDV
infection did not specifically suppress the ability of cells to respond
to interferon, and thereby allow interferon-resistant VSV replica-
tion. More likely, we propose that 5 days of HDV replication
rendered the cells resistant to VSV infection.
The present studies show that application of interferons can
significantly inhibit HDV entry and/or initiation of replication in
susceptible primary human hepatocytes. This study did not assay
possible additional late effects of interferons, such as on HDV
RNA-editing and HBV-dependent assembly of progeny HDV
particles.
The in vitro studies presented here rationalize the use of
interferons for in vivo therapies of chronic HDV, even with the use
of the highest tolerable doses. There still needs to be a search for
new strategies, possibly as combinations therapies, which could
improve treatment for chronic HDV. Maybe exogenous interfer-
ons can be replaced by immunomodulators such as IMO-2125,
which is a synthetic agonist of the toll-like receptor, TLR-9 [25].
The preS1 peptide is active in vitro and in vivo and has unique
advantages relative to interferons [20]. Farnesylation inhibitors
that act against HDV assembly have been tested in model systems
[26]. And maybe there is a role for siRNA that target the mRNA
for the essential small delta antigen [27].
Materials and Methods
Materials
Recombinant human interferon alpha 2b (Intron A) was from
Scherring and gamma were from Pestka Biological Laboratories.
Chemically synthesized HBV preS1 peptide was a gift of Stephan
Urban.
Cells and virus
We have previously described the derivation from human
embryonic kidney cells (HEK293 [28]) of two lines with
tetracycline (TET) inducible HDV sequences [12]. 293-dAg is
induced to express the small form of the HDV antigen, which is
essential for RNA accumulation. 293-HDV is derived from this
cell line, and contains transfected copies of HDV RNA that
replicate and increase in number when dAg is induced. For the
experiments of Fig. 1, these two cell lines were transfected with
poly(IC) (InvivoGen) for 6 h prior to a 24 h TET induction. Not
induced cells served as a control. Total RNA was extracted and
assayed by realtime PCR for interferon-beta1 and HDV RNA.
For HDV infection studies virus was assembled as previously
described [15]. Briefly, Huh7 cells [29] were transfected with two
plasmids, one to express the HBV envelope proteins and another
to initiate HDV genome replication. Media was collected between
days 6 and 13. After clarification, virus was precipitated by the
addition of polyethylene glycol to 10%, collected by centrifugation,
and resuspended in 1% of the original volume of media. Primary
human hepatocytes (PHH) in a 48-well format, were purchased
from either Cellzdirect or Celsis, and maintained in the
recommended hepatocyte growth medium. After exposure of cells
to virus, the media was removed and the cells washed two times.
The cells were harvested at 6 days post-infection. Vesicular
stomatitis virus (VSV) carrying a gene for green fluorescent protein
(GFP) was from the lab of Glenn Barber [30]. Hepatocyte cultures
were infected with VSV at a titer sufficient to infect 1% of cells, in
the absence or presence of recombinant interferons, for a period of
16 h, after which infection was assayed by counting GFP-positive
cells.
RNA extraction and realtime PCR
To assay HDV replication total RNA was extracted and
realtime PCR was performed after DNase treatments, as
previously described [24]. Assays for interferon beta-1 mRNA
used primers purchased from Applied Biosystems.
Protein extraction and immunoblot assays
Individual wells of PHH were exposed to interferons alpha or
gamma for periods of up to 24 h. The wells were then washed with
phosphate buffered saline and lysed in buffer containing TX100
and phosphatase inhibitors. Finally, samples were sonicated before
addition of Laemmli buffer and immunoblot analysis, as previously
described [31]. Chemi-luminescence assays were performed using
primary antibodies: Stat-1 from Becton-Dickinson, phosphoStat-1
from Upstate, beta-actin from Sigma, Mx1/2/3 and PKR B10
from Santa Cruz.
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